Fig. 1
CLEC3B expression was down-regulated in HCC. a The mRNA levels of CLEC3B in tumor tissues (T) and non-tumor tissues (N) of hepatocellular carcinoma patients in Gene Expression Omnibus (GEO) database online, they are GSE14520 (n = 455, P < 0.0001), GSE36376 (n = 433, P < 0.0001), GSE54236 (n = 160, P < 0.0001), GSE64041 (n = 125, P < 0.0001), GSE25097 (n = 557, P < 0.0001) and GSE76427 (n = 120, P < 0.0001), and TCGA-LIHC cohort (log10), paired (P < 0.0001) and unpaired (P < 0.0001), from left to right. b The mRNA levels of 39 cases of hepatocellular carcinoma and adjacent non-tumor tissues were determined by RT-PCR (P < 0.0001). c The protein levels of 22 cases of hepatocellular carcinoma (T) and paired adjacent non-tumor (N) tissues were determined by western blot (left), and the statistical value of corresponding protein level of CLEC3B (right) (P = 0.0033). d The immunohistochemistry (IHC) results of representative high and low expression of CLEC3B in tumor and the statistical value of IHC of CLEC3B expression in hepatocellular carcinoma (T) and paired adjacent non-tumor (N) tissues (P < 0.0001). e Relative quantity of CLEC3B in plasma of the normal (N, n = 8) and HCC (T, n = 8) patients (P = 0.0425). f Overall survival in hepatocellular carcinoma patients (left, n = 80, P = 0.0001) and TCGA-LIHC cohort (right, n = 370, P < 0.0001), based on CLEC3B expression level, were calculated by Kaplan–Meier. g The relative proportion of patients with high CLEC3B expression increased from vessel metastatic patients (positive) to non-vessel metastatic patients (negative) (P = 0.005). *, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., not significant